Facing persistently high interest rates and a shifting regulatory landscape, healthcare and life sciences dealmakers are rethinking their approaches to inorganic growth.

Join us for an exclusive webinar where industry leaders from corporate development and advisory will unpack today’s top economic and strategic pressures. Our expert panel will explore how corporate and private equity dealmakers are:

• Factoring supply chain and tariff disruptions into due diligence
• Identifying subsectors drawing renewed investor interest
• Navigating evolving antitrust enforcement
• Mitigating valuation gaps amid ongoing market uncertainty